home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

468.94 -3.12 (-0.66%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

A Look Into United Therapeutics Inc's Price Over Earnings ↗

October 03, 2024

Via Benzinga

U.S. Stock: United Therapeutics Corp ↗

September 25, 2024

United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease.

Via Talk Markets

Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today ↗

September 24, 2024

Via Benzinga

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting

September 24, 2024

From United Therapeutics Corporation

Via Business Wire

Key Takeaways From United Therapeutics Analyst Ratings ↗

September 23, 2024

Via Benzinga

The Analyst Verdict: United Therapeutics In The Eyes Of 8 Experts ↗

August 20, 2024

Via Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today ↗

August 05, 2024

Via Benzinga

Navigating 9 Analyst Ratings For United Therapeutics ↗

July 25, 2024

Via Benzinga

United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever

September 10, 2024

From United Therapeutics Corporation

Via Business Wire

FDA Battles Backlog of Drug Factory Inspections Since COVID-19 ↗

September 06, 2024

FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.

Via Benzinga

Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark ↗

September 05, 2024

Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86.

Via Investor's Business Daily

Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers ↗

August 29, 2024

Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers.

Via Investor's Business Daily

Ambarella To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

August 28, 2024

Via Benzinga

United Therapeutics Corporation to Present at Upcoming Investor Conferences

August 28, 2024

From United Therapeutics Corporation

Via Business Wire

Biohaven Stock Earns Relative Strength Rating Upgrade ↗

August 21, 2024

Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91.

Via Investor's Business Daily

SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating ↗

August 21, 2024

A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance.

Via Investor's Business Daily

Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings ↗

August 19, 2024

Renaissance Technologies, the hedge fund founded by legendary mathematician and former NSA code breaker Jim Simons, recently disclosed its latest stock holdings in a 13F filing with the U.S. Securities...

Via Benzinga

ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday ↗

August 19, 2024

Via Benzinga

Why Liquidia Stock Just Reversed Its Seven-Day Sprint And Crashed 38% ↗

August 19, 2024

The company is hoping to launch a drug that rivals United Therapeutics' Tyvaso DPI.

Via Investor's Business Daily

Rivian, Chipotle Mexican And Sirius XM Are Among Top 10 Large Cap Losers Last Week (Aug 11-Aug 17): Are The Others In Your Portfolio? ↗

August 18, 2024

Ten large-cap stocks were the worst performers last week, with TME, MBLY, RIVN, CMG, LINE, SIRI, HSY, BAX, BR, and UTHR all seeing declines.

Via Benzinga

NASDAQ:UTHR is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

August 15, 2024

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is probably undervalued for the fundamentals it is displaying.

Via Chartmill

3 Biotech Stocks on Track for 50% Returns (or More) by 2028 ↗

August 04, 2024

Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028!

Via InvestorPlace

UTHR Stock Earnings: United Therapeutics Misses EPS, Beats Revenue for Q2 2024 ↗

July 31, 2024

UTHR stock results show that United Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

United Therapeutics Stock Skids On Mixed Second-Quarter Results ↗

July 31, 2024

The company's earnings came in far below expectations, though sales easily beat.

Via Investor's Business Daily

United Therapeutics Corporation Reports Second Quarter 2024 Financial Results

July 31, 2024

From United Therapeutics Corporation

Via Business Wire

The 3 Best 3D Bioprinting Stocks to Buy Now ↗

July 26, 2024

These are three of the best 3D bioprinting stocks to buy as the technology begins to hit its stride in the health care sector.

Via InvestorPlace

Beam Therapeutics Stock Earns RS Rating Jump To 85 ↗

July 24, 2024

On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85.

Via Investor's Business Daily

United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024

July 24, 2024

From United Therapeutics Corporation

Via Business Wire

Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today ↗

July 22, 2024

Via Benzinga

Biotech Arvinas Stock Earns 82 RS Rating ↗

July 17, 2024

The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com